T HE METABOLIC SYNDROME, characterized by the clustering of hypertension, dyslipidemia, visceral obesity, and insulin resistance, is now regarded as a risk factor for cardiovascular morbidity and mortality 1 and is recognized as a new means of detecting coronary heart disease (CHD) risk. 2 The metabolic syndrome prevalence is rising rapidly concomitant with the obesity epidemic, fueled by physical inactivity and unhealthy eating patterns. 3 Rates of metabolic syndrome-associated CHD are projected to increase substantially. 3, 4 Insulin resistance is regarded by many researchers as a key component of the metabolic syndrome, with interesting parallels to the insulin-resistant type of diabetes. Both are related to visceral obesity 5 and both are associated with hypertension; however, lean hypertensive patients can be insulin resistant. 5, 6 Additional findings have drawn a link to the sympathoadrenal system, suggesting that neurohumoral activation may be causally involved. [5] [6] [7] Visceral obesity, insulin resistance, and diabetes are also associated with a proinflammatory state, 8 which is associated with increased CHD risk. 9 However, whether there is an underlying causal mechanism of the metabolic syndrome such as neurohumoral activation or whether it simply represents a cluster of risk factors that are not causally related is unknown.
Randomized controlled trials of transcendental meditation (TM) have demonstrated a blood pressure-lowering effect similar to a first-line antihypertensive medication compared with a control intervention of health education (HE). [10] [11] [12] [13] [14] These results suggest that TM may have a beneficial impact on certain underlying risk factors for CHD, including blood pressure, via neurohumoral alterations in the sympathetic nervous system activity. Whether such effects occur on other CHD risk factors, including those encompassed within the metabolic syndrome, has not been previously studied. Therefore, we undertook a randomized, controlled trial of 16 weeks of TM compared with HE in 103 patients with stable CHD on the main components of the metabolic syndrome and CHD, including blood pressure, lipoprotein profile, and insulin resistance determined by homeostasis model assessment (HOMA) (calculated as follows: [(fasting plasma glucose level [in milligrams per deciliter] ϫ fasting plasma insulin level [in microunits per milliliter]) ϫ0.0552]/22.5, as well as endothelial function measured by brachial artery reactivity testing (BART) and cardiac autonomic nervous system activity measured by heart rate variability (HRV).
METHODS

STUDY DESIGN AND POPULATION
The study design was a randomized, single-blind, attentioncontrolled trial. Patients were recruited from a supervised cardiac exercise and rehabilitation program at Cedars-Sinai Medical Center and the surrounding community. We included women and men older than 18 years, with CHD documented by prior myocardial infarction, coronary artery bypass surgery, coronary angiography, or angioplasty. Exclusion criteria consisted of unstable coronary syndromes, congestive heart failure greater than New York Heart Association class III, renal failure, acute myocardial infarction in the preceding 3 months, atrial fibrillation or a predominantly paced rhythm, prior TM, or current stress management practice. The study was approved by the institutional review board, and all participants gave written informed consent.
STUDY PROTOCOL
Randomization to TM or to HE for 16 weeks was performed via a computerized program with blocking, whereby eligible patients were grouped according to age (Ն65 years) and lowdensity lipoprotein cholesterol levels (Ն120 mg/dL [Ն6.66 mmol/L]) and assigned to treatment group accordingly. Once a group of 10 to 16 patients was randomized (ie, 5-8 per treatment group), a new cohort would be formed and begin the respective interventions concomitantly. The outcome data were collected and analyzed by personnel blinded to patient treatment status. At study entry and exit, after an overnight fast, patients underwent a medical history review, including cardiac risk factors, physical activity level, psychosocial variables, and medication assessment, along with BART, 24-hour ambulatory Holter monitoring of HRV, and blood sampling. Compliance with the TM and HE programs was assessed by class attendance and self-reported compliance. The blood pressure protocol included 5 minutes of sitting quietly followed by blood pressure measurement using a mercury sphygmomanometer 3 times at 1-minute intervals, and then averaged for screening and entry and exit visits. 15 Body weight and height were measured to the nearest 0.1 kg and 0.1 cm, respectively, and body mass index (BMI) was calculated as weight in kilograms divided by the square of height in meters. Psychosocial assessment included indicators of hostility, 16 typical depression, 17 trait anxiety and anger, 18 and life stress.
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TM AND HE INTERVENTIONS
The TM technique is a meditation modality restored from the ancient Vedic tradition in India 16 and taught worldwide since 1957. 20 The highly standardized and reproducible TM teaching materials were used to ensure quality control and consistency. 
BLOOD TESTING AND HOMA PROTOCOL
Levels of total plasma cholesterol, triglycerides, and highdensity lipoprotein cholesterol were determined as previously published. 21 Plasma glucose and plasma insulin concentrations were measured using a commercially available glucose reagent (Elan Corporation, Dublin, Ireland) 22 and automated immunoassay instrument and ultrasensitive insulin kit (Beckman-Coulter, Fullerton, Calif), 23 respectively. Assays were performed in batches and in duplicate. The degree of insulin resistance in each subject was estimated by means of the HOMA using the following formula: ( 
BART PROTOCOL
Patients fasted overnight and were withdrawn from vasoactive medication therapy 24 to 48 hours before testing, as per our standard protocol. 26 We assessed (1) peripheral flowmediated, endothelium-dependent vasomotion and (2) endothelium-independent vasodilation in the brachial artery using a noninvasive high-resolution B-mode ultrasonography technique, as previously described, 27 using our validated analytical methods to measure flow-mediated dilation.
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HRV PROTOCOL
Results of Holter monitoring were collected during a 24-hour period using our previously validated and published methods. 29 A 24-hour tape was considered eligible for this study if it had more than 12 hours of analyzable data and half of the nighttime and daytime periods analyzable, and if more than 50% of the recording demonstrates sinus rhythm. The HRV was analyzed using commercially available software (Marquette software, version 002A; Marquette University, Milwaukee, Wis).
STATISTICAL ANALYSIS
Data are presented as mean±SD for continuous variables and as frequencies and percentages for categorical variables. Comparison of treatment groups at entry and exit was performed using paired and unpaired t test for continuous data and 2 and Fisher exact tests for discrete data. The Wilcoxon signed rank and rank sum tests were used for the analysis of nonnormally distributed continuous variables. Multivariable regression was performed using general linear methods to determine least square means of the dependent variable of interest, adjusting for independent variables as appropriate. To control for the effect that entry measurements may exert on exit measurements, models were adjusted for entry values. Bonferroni adjustment for multiple outcomes was used to adjust the significance level for the 3 spectral domain HRV outcomes hypothesized to be affected by the intervention. A P value less than .05 was required for statistical significance. Analyses were performed using SAS software, version 8.1 (SAS Institute Inc, Cary, NC).
RESULTS
Overall, 103 patients enrolled and 84 (82%) completed the study. Among the 19 dropouts, 12 were in the HE group and 15 dropped out before starting either intervention owing to lack of interest in group assignment. Compliance, assessed by class attendance, was 97% (7 dropouts) in the TM and 88% (12 dropouts) in the HE groups (P= . 19) . No adverse events were reported.
Entry clinical characteristics for the TM and HE groups are given in Table 1 and demonstrate a predominantly male, older CHD population with high rates of treated hypertension, dyslipidemia, and obesity. Few of the patients had diabetes. Medical management of CHD was near-optimal, with high rates of lipid-lowering, angiotensin-converting enzyme inhibitor, and ␤-blocker medication use. Most patients performed regular physical activity in a cardiac rehabilitation program.
STUDY OUTCOMES Blood Pressure, Lipoprotein Levels, and Other Cardiac Risk Factors
We observed significant group differences in exit systolic blood pressure and mean arterial blood pressure in the TM compared with the HE group ( Abbreviations: CRP, C-reactive protein; HDL-C, high-density lipoprotein cholesterol; HE, health education; LDL-C, low-density lipoprotein cholesterol; TM, transcendental meditation. SI conversion factor: To convert cholesterol to millimoles per liter, multiply by 0.0259; triglyceride to millimoles per liter, multiply by 0.0113.
*Data are expressed as mean ± SD. For the HE group, n = 51 at entry and n = 39 at exit; for the TM group, n = 52 at entry and n = 45 at exit.
†Determined . There were no differences from entry to exit levels of lipoproteins and highsensitivity C-reactive protein or BMI in either treatment group, but a marginally significant increase in physical activity level was observed in the HE group (P=.09). The HE group was significantly more depressed and angry compared with the TM group at trial entry, and this did not change at exit. There was no difference in self-reported life stress, which was low overall in both groups. Adjustment for entry variables, medication, or intervention completion did not alter any of these results.
Fasting Blood Glucose and Insulin Levels and HOMA
Fasting blood glucose and insulin levels were beneficially improved from entry to exit in the TM compared with the HE group (Figure) . Unadjusted ⌬HOMA from entry to exit within the TM group was −0.79±2.04 (P=.01) compared with 0.60±2.84 (P=.42) in the HE group, and the ⌬HOMA was significantly different between the 2 intervention groups (P = .03). This beneficial improvement remained after removing diabetic patients from the analysis (⌬HOMA, −0.49±1. 17 
Brachial Artery Reactivity Testing
There were no significant differences in the BART variables from entry to exit, or between groups ( Table 3) . Similar results were found when exit baseline diameters varying by more than 15% from entry baseline diameter were excluded from the analyses (1 patient in the TM group and 3 in the HE group). Adjustment for entry BART variables and medications did not alter the results. For differences between the transcendental meditation (TM) vs health education (HE) groups at exit, P =.03 for insulin resistance; P =.06 for glucose level; and P =.02 for insulin level. For within-group change, P = .06 for insulin resistance in the TM group; =P =.04 for glucose level in the TM group. For the TM group, n = 52 at entry and n=45 at exit; for the HE group, n = 51 at entry and n =39 at exit. To convert glucose to millimoles per liter, multiply by 0.0555; insulin to picomoles per liter, multiply by 6.945. Abbreviations: BART, brachial artery reactivity testing; ⌬, change; FMD, flow-mediated dilation (defined as [(diameter after cuff deflation minus diameter at baseline) divided by diameter at baseline] ϫ 100); HE, health education; TM, transcendental meditation.
*Unless otherwise indicated, data are expressed as mean ± SD. †Adjusted for age, sex, baseline FMD, change in systolic blood pressure from entry to exit, calcium channel blocker use, history of myocardial infarction, and baseline depression and anger scores. Data are expressed as least squares mean ± SE.
Heart Rate Variability
There were no statistically significant differences between the TM and HE groups with respect to unadjusted entry and exit HRV measures of the spectral or time domain measures. Among the spectral domain measures (Table 4) , after adjustment for age, sex, baseline HRV measure, history of myocardial infarction, BMI at study exit, physical activity level at study exit, and baseline depression and anger scores, there was a statistically significant difference in ⌬high-frequency power between the TM and HE groups (P = .02) ( Table 4) . After Bonferroni adjustment of the P value, the group difference in ⌬high-frequency power became marginally statistically different (P = .07). There were also marginally statistically significant differences in adjusted ⌬total power and ⌬low-frequency measures (both P = .09).
COMMENT
The present study demonstrated that 16 weeks of TM resulted in significant beneficial effects on adjusted blood pressure, insulin resistance, and cardiac autonomic nervous system tone compared with the HE control group. These physiological effects were accomplished without changes in body weight, medication, or psychosocial variables and despite a marginally statistically significant increase in physical activity in the HE group. These results suggest that TM may modulate the physiological response to stress via neurohumoral activation, which may be a novel therapeutic target for the treatment of CHD.
Additional lines of evidence have indirectly suggested that neurohumoral activation may be a common mechanistic pathway for the metabolic syndrome. Previous work by Reaven et al 5 and Brook and Julius 6 has suggested that sympathoadrenal system activation is linked with the metabolic syndrome. Visceral obesity, insulin resistance, and diabetes are also associated with a proinflammatory state 4, 8 that is linked with elevated CHD risk. 9 Post hoc analyses of large randomized trials of angiotensin-converting enzyme inhibitors and statins in atrisk subjects have demonstrated reductions in the onset of diabetes. [30] [31] [32] [33] Because these classes of medications appear to interrupt important neurohumoral and inflammatory pathways, such results suggest a common causal mechanism for the metabolic syndrome. The present study results expand this understanding and demonstrate that TM, which is believed to reduce sympathoadrenal system activation, beneficially alters the blood pressure and insulin resistance components of the metabolic syndrome. Although a previous meta-analysis demonstrated that educational psychosocial interventions improve glucose control in diabetic patients via improved compliance with medical regimens, 34 the present study results demonstrate an improvement in insulin resistance in nondiabetic patients that was not related to medication change.
These current results also expand our causal understanding of the role of stress in the rising epidemic of the metabolic syndrome. Although current low levels of physical activity, unhealthy eating habits, and resultant obesity are triggers for this epidemic, the demands of modern society may also be responsible for higher levels of chronic stress. 35 Stress activates the neurohumoral system, specifically the sympathoadrenal system and the hypothalamicpituitary-adrenocortical axis that involves catecholamine release, vagal withdrawal, cortisol secretion, and upregulation of the renin-angiotensin system. 36 Acute psychological stress has also been demonstrated to increase interleukin 6 levels, 37 possibly owing to stress-induced catecholamine activiation. Interleukin 6 also appears to activate the hypothalamic-pituitary-adrenocortical axis, increasing the hypothalamic secretion of corticotrophinreleasing hormone and responsiveness of the anterior pituitary release of corticotropin and adrenal secretion of cortisol. 38 A recent case-control study 39 of 183 subjects with metabolic syndrome demonstrating neurohumoral activation associated with chronic environmental stress further implicates a neurohumoral pathway as a common causal mechanism and potential target. Our results, demonstrating beneficial physiological effects of TM in the absence of effects on psychosocial variables, suggest that TM may modulate response to stress rather than alter the stress itself, similar to the physiological impact of exercise conditioning.
We did not observe group differences in the outcome variables of peripheral endothelial function, suggesting a lack of TM efficacy on this physiological variable. However, given our blood pressure and insulin resistance results, which should have contributed to improved endothelial function, 40, 41 it is possible that other factors may have contributed to these negative results. The high prevalence of statin use and near-optimal low-density lipoprotein cholesterol levels may have precluded any incremental TM benefit via the neurohumoral-inflammatory pathways. Indeed, our mean high-sensitivity C-reactive ) 6.55 ± 0.79 6.56 ± 0.95 .58 High-frequency power, log(ms Abbreviations: ⌬, change; HE, health education; HRV, heart rate variability; TM, transcendental meditation.
*The spectral domain data contain the total power (0.01-1.00 Hz), low-frequency band (0.04 to Ͻ0.15 Hz), and high-frequency band (0.15 to Ͻ0.40 Hz) on a 24-hour basis. Unless otherwise indicated, data are expressed as mean ± SD.
†Adjusted for age, sex, baseline HRV variable, body mass index at exit, physical activity level, history of myocardial infarction, and depression and anger scores at baseline. Data are expressed as least squares mean ± SE. The P values are Bonferroni adjusted to account for multiple outcome comparisons.
protein measure was relatively low for a CHD cohort and demonstrated no differences in response to the intervention. Although a significant effect was observed in HRV as hypothesized, this may have been minimized by the HE group's physical activity improvement because of the strong role exercise conditioning plays in cardiac autonomic nervous system tone.
The present study results add to those of previous randomized trials using TM for reduction of blood pressure. Although earlier meta-analyses questioned the efficacy of relaxation therapy 42 in treating hypertension, a more recent meta-analysis 43 concluded that individualized cognitivebehavioral approaches were comparable in magnitude to drug treatment effects in reducing blood pressure. A small trial demonstrated significant reductions in medication requirements in 39 hypertensive patients randomized to a 6-week multicomponent cognitive-behavioral intervention that included temperature biofeedback, progressive muscle relaxation, and therapy for stress and anger management. 44 Specific to TM, previous randomized trials [10] [11] [12] [13] [14] demonstrated decreased systolic and diastolic blood pressure compared with controls in sample sizes of 35 to 157 hypertensive and prehypertensive subjects. Our results are consistent with this body of literature, particularly with regard to nonhypertensive and prehypertensive subjects, because our CHD group did not have elevated mean blood pressure at study entry and only half had a history of hypertension. Additional studies have examined the impact of stress management techniques on CHD outcomes. Although a number of psychological and group support trials 45 have not consistently demonstrated benefit for CHD outcomes such as nonfatal myocardial infarction and death, one study 46 that used specific mind-body techniques has demonstrated promising results. Pooled data from 2 published randomized controlled trials that compared the effects of mind-body interventions (including TM, mindfulness meditation, relaxation response, HE, and usual care) on blood pressure demonstrated adjusted relative hazard rates for TM compared with the control intervention of 0.77 (P = .04) for all-cause mortality and 0.70 (P=.045) for cardiovascular mortality. 47, 48 A recent prospective trial by Blumenthal and coworkers 49 found that a multimodality psychological intervention in CHD patients had fewer recurrent coronary events at 5-year follow-up compared with those receiving usual care. Prospective trials performed with an adequate sample size are needed to address this issue.
Limitations of this trial included its relatively small size and short duration, which may have minimized the intervention effects. The patient population may not be representative of the general CHD population owing to the relatively low levels of low-density lipoprotein cholesterol and high physical activity levels. We used an indirect measure of insulin resistance (HOMA) that is increasingly being used as an outcome in clinical trials 50, 51 ; however, our results may have underestimated our effects. We did not perform ambulatory blood pressure monitoring and cannot exclude the possibility that the TM was effective only for reducing clinic blood pressure measures, although this is unlikely owing to previous work demonstrating efficacy (P=.04). 13 We did not measure waist circumference, and this limits our ability to assess the metabolic syndrome. Our self-reported psychosocial stress measures may have been insensitive to change. Our subgroup analyses were underpowered to test specific hypotheses in diabetic subjects, women, and the elderly (older than 75 years).
CONCLUSIONS
The present trial results demonstrate that 16 weeks of TM significantly reduces the adjusted blood pressure and insulin resistance components of the metabolic syndrome and has a positive impact on cardiac autonomic tone in subjects with stable, optimally managed CHD. These results suggest that neurohumoral pathways may be mechanistically involved in the metabolic syndrome. Our findings also suggest that interventions that target neurohumoral pathways, especially via meditation or related techniques, may be beneficial for CHD reduction and should be tested in larger, more adequately powered clinical trials.
